Changing dynamics of bloodstream infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium in Germany, 2017-2023: a continued burden of disease approach

被引:1
|
作者
Brinkwirth, Simon [1 ,2 ,3 ]
Feig, Marcel [4 ]
Noll, Ines [1 ]
Eckmanns, Tim [1 ]
Doerre, Achim [1 ,2 ]
Haller, Sebastian [1 ]
Willrich, Niklas [1 ]
机构
[1] Robert Koch Inst, Dept Infect Dis Epidemiol, Healthcare Associated Infect Surveillance Antibiot, See Str 10, D-13353 Berlin, Germany
[2] Robert Koch Inst, Dept Infect Dis Epidemiol, Postgrad Training Appl Epidemiol PAE, See Str 10, D-13353 Berlin, Germany
[3] European Ctr Dis Prevent & Control ECDC, ECDC Fellowship Programme, Field Epidemiol Path EPIET, Stockholm, Sweden
[4] Robert Koch Inst, Unit MF2 Domain Spec Data Competence Ctr, Dept Methods Dev Res Infrastruct & Informat Techno, See Str 10, D-13353 Berlin, Germany
来源
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL | 2025年 / 14卷 / 01期
关键词
GENDER-DIFFERENCES; EPIDEMIOLOGY; CARRIAGE;
D O I
10.1186/s13756-025-01522-9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundAntimicrobial resistance is a global threat to public health, with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREfm) being major contributors. Despite their clinical impact, comprehensive assessments of changes of the burden of bloodstream infections in terms of Disability-Adjusted Life Years (DALYs) and attributable deaths over time are lacking, particularly in Germany.MethodsWe used data from the Antimicrobial Resistance Surveillance system, which covered about 30% of German hospitals. Bloodstream infections were defined by a VREfm or MRSA-positive blood culture. We estimated incidences as a first step to further use these rates to calculate DALYs and attributable deaths using the Burden of Communicable Disease in Europe toolkit. The analysis included stratification by age, sex and region.ResultsFrom 2017 to 2023, 6262 MRSA and 5442 VREfm blood culture-positive isolates were identified. The incidence of MRSA bloodstream infections decreased from 4.0 to 2.1 per 100,000 population, with estimated DALYs decreasing from 14.6 to 8.6 per 100,000 and attributable deaths from 591 to 316. Conversely, VREfm-BSI incidence doubled from 1.7 to a peak of 3.0 (2021) before declining back to 1.7 per 100,000 in 2023, with estimated DALYs increasing from 8.9 to 16.5 and then decreasing to 8.5 per 100,000 and attributable deaths increasing from 317 to 327. Men and people over 60 years had the highest burden, with noticeable regional differences.ConclusionMRSA and VREfm bloodstream infections followed different trends in the past and now present a comparable burden in Germany. Both pathogens pose a significant threat, particularly to hospitalised older aged men. Our findings highlight the need for targeted prevention and continued surveillance of MRSA and VREfm to reduce infections and their impact.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] In vitro susceptibility of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium to daptomycin and other antibiotics
    Z. Samra
    O. Ofir
    H. Shmuely
    European Journal of Clinical Microbiology & Infectious Diseases, 2007, 26 : 363 - 365
  • [2] In vitro susceptibility of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium to daptomycin and other antibiotics
    Samra, Z.
    Ofir, O.
    Shmuely, H.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2007, 26 (05) : 363 - 365
  • [3] Germany's Burden of Disease of Bloodstream Infections Due to Vancomycin-Resistant Enterococcus faecium between 2015-2020
    Brinkwirth, Simon
    Martins, Sofie
    Ayobami, Olaniyi
    Feig, Marcel
    Noll, Ines
    Zacher, Benedikt
    Eckmanns, Tim
    Werner, Guido
    Willrich, Niklas
    Haller, Sebastian
    MICROORGANISMS, 2022, 10 (11)
  • [4] In vitro antimicrobial activity of propolis against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium
    Kilic, A
    Baysallar, M
    Besirbellioglu, B
    Salih, B
    Sorkun, K
    Tanyuksel, M
    ANNALS OF MICROBIOLOGY, 2005, 55 (02) : 113 - 117
  • [5] Antibiotic and biocide resistance in methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus
    Suller, MTE
    Russell, AD
    JOURNAL OF HOSPITAL INFECTION, 1999, 43 (04) : 281 - 291
  • [6] Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus
    Belley, Adam
    Harris, Robert
    Beveridge, Terry
    Parr, Tom, Jr.
    Moeck, Gregory
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (02) : 800 - 804
  • [7] Epidemiology of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a rural state
    Polgreen, Philip M.
    Beekmann, Susan E.
    Chen, Yi Yi
    Doern, V.
    Pfaller, Michael A.
    Brueggemann, Angela B.
    Herwaldt, Loreen A.
    Diekema, Daniel J.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2006, 27 (03): : 252 - 256
  • [8] Vancomycin-resistant enterococcus (VRE) vs Methicillin-resistant Staphylococcus Aureus (MRSA)
    Ashwin, K. S.
    Muralidharan, N. P.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2015, 33 : S166 - S167
  • [9] Evaluation of contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus
    Bardossy, Ana Cecilia
    Alsafadi, Muhammad Yasser
    Starr, Patricia
    Chami, Eman
    Pietsch, Jennifer
    Moreno, Daniela
    Johnson, Laura
    Alangaden, George
    Zervos, Marcus
    Reyes, Katherine
    AMERICAN JOURNAL OF INFECTION CONTROL, 2017, 45 (12) : 1369 - 1371
  • [10] Control of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in hospitalized children
    Fisher, MC
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (09) : 825 - 826